Molecular Targeting Therapy against EGFR Family in Breast Cancer: Progress and Future Potentials
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Molecular Targeting Therapy against EGFR Family in Breast Cancer: Progress and Future Potentials
Authors
Keywords
-
Journal
Cancers
Volume 11, Issue 12, Pages 1826
Publisher
MDPI AG
Online
2019-11-21
DOI
10.3390/cancers11121826
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- HER2 Directed Antibody-Drug-Conjugates beyond T-DM1 in Breast Cancer
- (2019) Gabriel Rinnerthaler et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Near-Infrared Photoimmunotherapy of Cancer
- (2019) Hisataka Kobayashi et al. ACCOUNTS OF CHEMICAL RESEARCH
- CAR-T Engineering: Optimizing Signal Transduction and Effector Mechanisms
- (2019) Emiliano Roselli et al. BIODRUGS
- Treatment of advanced HER2-positive breast cancer: 2018 and beyond
- (2018) Noam Pondé et al. CANCER TREATMENT REVIEWS
- Universal Chimeric Antigen Receptors for Multiplexed and Logical Control of T Cell Responses
- (2018) Jang Hwan Cho et al. CELL
- STAT3 and apoptosis challenges in cancer
- (2018) Nazanin Fathi et al. INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES
- Structural insights into the mechanism of action of a biparatopic anti-HER2 antibody
- (2018) Vaheh Oganesyan et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Mechanisms of receptor tyrosine kinase activation in cancer
- (2018) Zhenfang Du et al. Molecular Cancer
- Receptor tyrosine kinases and downstream pathways as druggable targets for cancer treatment: the current arsenal of inhibitors
- (2018) Wagner Ricardo Montor et al. Molecular Cancer
- Simultaneous targeting of EGFR, HER2, and HER4 by afatinib overcomes intrinsic and acquired cetuximab resistance in head and neck squamous cell carcinoma cell lines
- (2018) Ines De Pauw et al. Molecular Oncology
- Immune recognition of somatic mutations leading to complete durable regression in metastatic breast cancer
- (2018) Nikolaos Zacharakis et al. NATURE MEDICINE
- Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
- (2018) Freddie Bray et al. CA-A CANCER JOURNAL FOR CLINICIANS
- STAT3 activation confers trastuzumab-emtansine (T-DM1) resistance in HER2-positive breast cancer
- (2018) Lei Wang et al. CANCER SCIENCE
- HER2-positive breast cancer
- (2017) Sibylle Loibl et al. LANCET
- 11 years' follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial
- (2017) David Cameron et al. LANCET
- Emerging functions of the EGFR in cancer
- (2017) Sara Sigismund et al. Molecular Oncology
- Engineering Natural Killer Cells for Cancer Immunotherapy
- (2017) Katayoun Rezvani et al. MOLECULAR THERAPY
- Afatinib radiosensitizes head and neck squamous cell carcinoma cells by targeting cancer stem cells
- (2017) Muzafar A. Macha et al. Oncotarget
- Efficacy and safety of lapatinib and trastuzumab for HER2-positive breast cancer: a systematic review and meta-analysis of randomised controlled trials
- (2017) Zhi-qiao Xu et al. BMJ Open
- Epidermal Growth Factor Receptor Cell Proliferation Signaling Pathways
- (2017) et al. Cancers
- A randomized, double-blind phase II trial of exemestane with or without MM-121 in postmenopausal women with locally advanced or metastatic estrogen receptor-positive (ER+) and/or progesterone receptor-positive (PR+), HER2-negative breast cancer.
- (2017) V. M. Moyo et al. JOURNAL OF CLINICAL ONCOLOGY
- Panitumumab in combination with FEC 100 (5-fluorouracil, epidoxorubicin, cyclophosphamide) followed by docetaxel (T) in patients with operable, triple-negative breast cancer (TNBC): Preliminary results of a multicenter neoadjuvant pilot phase II study.
- (2017) J. Nabholtz et al. JOURNAL OF CLINICAL ONCOLOGY
- HER3 as a Therapeutic Target in Cancer
- (2016) Niki Karachaliou et al. BIODRUGS
- Trastuzumab in the Treatment of Breast Cancer
- (2016) Sofia Maximiano et al. BIODRUGS
- Retrospective study of the efficacy and safety of neoadjuvant docetaxel, carboplatin, trastuzumab/pertuzumab (TCH-P) in nonmetastatic HER2-positive breast cancer
- (2016) Shruti R. Tiwari et al. BREAST CANCER RESEARCH AND TREATMENT
- Antibody-drug conjugates—an emerging class of cancer treatment
- (2016) Nikolaos Diamantis et al. BRITISH JOURNAL OF CANCER
- The role of HER2, EGFR, and other receptor tyrosine kinases in breast cancer
- (2016) Jennifer L. Hsu et al. CANCER AND METASTASIS REVIEWS
- Tandem CAR T cells targeting HER2 and IL13Rα2 mitigate tumor antigen escape
- (2016) Meenakshi Hegde et al. JOURNAL OF CLINICAL INVESTIGATION
- Preclinical and clinical studies on afatinib in monotherapy and in combination regimens: Potential impact in colorectal cancer
- (2016) I. De Pauw et al. PHARMACOLOGY & THERAPEUTICS
- Photothermal therapy with immune-adjuvant nanoparticles together with checkpoint blockade for effective cancer immunotherapy
- (2016) Qian Chen et al. Nature Communications
- Anti-EGFR monoclonal antibodies and EGFR tyrosine kinase inhibitors as combination therapy for triple-negative breast cancer
- (2016) Abderrahim El Guerrab et al. Oncotarget
- Cancer Hallmarks, Biomarkers and Breast Cancer Molecular Subtypes
- (2016) Xiaofeng Dai et al. Journal of Cancer
- Non-HER2 signaling pathways activated in resistance to anti-HER2 therapy in breast cancer
- (2015) Adela Madrid-Paredes et al. BREAST CANCER RESEARCH AND TREATMENT
- Original paper Prognostic value of PIK3CA mutation status, PTEN and androgen receptor expression for metastasis-free survival in HER2-positive breast cancer patients treated with trastuzumab in adjuvant setting
- (2015) Agnieszka Adamczyk et al. POLISH JOURNAL OF PATHOLOGY
- Afatinib, an Irreversible EGFR Family Inhibitor, Shows Activity Toward Pancreatic Cancer Cells, Alone and in Combination with Radiotherapy, Independent of KRAS Status
- (2015) Florence Huguet et al. Targeted Oncology
- Photothermal ablation of bone metastasis of breast cancer using PEGylated multi-walled carbon nanotubes
- (2015) Zhen Lin et al. Scientific Reports
- Role of ErbB Receptors in Cancer Cell Migration and Invasion
- (2015) Aline Appert-Collin et al. Frontiers in Pharmacology
- Near Infrared Photoimmunotherapy Targeting EGFR Positive Triple Negative Breast Cancer: Optimizing the Conjugate-Light Regimen
- (2015) Tadanobu Nagaya et al. PLoS One
- Neratinib overcomes trastuzumab resistance in HER2 amplified breast cancer
- (2015) Alexandra Canonici et al. Oncotarget
- Multicentric neoadjuvant phase II study of panitumumab combined with an anthracycline/taxane-based chemotherapy in operable triple-negative breast cancer: identification of biologically defined signatures predicting treatment impact
- (2014) J. M. Nabholtz et al. ANNALS OF ONCOLOGY
- Role of human epidermal growth factor receptor 2 in gastric cancer: Biological and pharmacological aspects
- (2014) Jan Trøst Jørgensen WORLD JOURNAL OF GASTROENTEROLOGY
- Treatment of HER2-positive breast cancer
- (2013) Maria Cristina Figueroa-Magalhães et al. BREAST
- Oncogenic ERBB3 Mutations in Human Cancers
- (2013) Bijay S. Jaiswal et al. CANCER CELL
- RG7116, a Therapeutic Antibody That Binds the Inactive HER3 Receptor and Is Optimized for Immune Effector Activation
- (2013) C. Mirschberger et al. CANCER RESEARCH
- HER2 and lung cancer
- (2013) Lorenza Landi et al. Expert Review of Anticancer Therapy
- STAT3 activation in HER2-overexpressing breast cancer promotes epithelial-mesenchymal transition and cancer stem cell traits
- (2013) SEYUNG S. CHUNG et al. INTERNATIONAL JOURNAL OF ONCOLOGY
- Randomized Phase II Study of the Anti–Epidermal Growth Factor Receptor Monoclonal Antibody Cetuximab With Cisplatin Versus Cisplatin Alone in Patients With Metastatic Triple-Negative Breast Cancer
- (2013) José Baselga et al. JOURNAL OF CLINICAL ONCOLOGY
- ESR1 ligand-binding domain mutations in hormone-resistant breast cancer
- (2013) Weiyi Toy et al. NATURE GENETICS
- Targeting triple-negative breast cancer: optimising therapeutic outcomes
- (2012) K. Gelmon et al. ANNALS OF ONCOLOGY
- Safety and efficacy of neratinib (HKI-272) plus vinorelbine in the treatment of patients with ErbB2-positive metastatic breast cancer pretreated with anti-HER2 therapy
- (2012) A. Awada et al. ANNALS OF ONCOLOGY
- A phase II study of afatinib (BIBW 2992), an irreversible ErbB family blocker, in patients with HER2-positive metastatic breast cancer progressing after trastuzumab
- (2012) Nancy U. Lin et al. BREAST CANCER RESEARCH AND TREATMENT
- Targeting the EGFR signaling pathway in cancer therapy
- (2012) Parthasarathy Seshacharyulu et al. EXPERT OPINION ON THERAPEUTIC TARGETS
- Dual Targeting of ErbB2 and MUC1 in Breast Cancer Using Chimeric Antigen Receptors Engineered to Provide Complementary Signaling
- (2012) Scott Wilkie et al. JOURNAL OF CLINICAL IMMUNOLOGY
- TBCRC 001: Randomized Phase II Study of Cetuximab in Combination With Carboplatin in Stage IV Triple-Negative Breast Cancer
- (2012) Lisa A. Carey et al. JOURNAL OF CLINICAL ONCOLOGY
- Antitumor Activity of a Novel Bispecific Antibody That Targets the ErbB2/ErbB3 Oncogenic Unit and Inhibits Heregulin-Induced Activation of ErbB3
- (2012) C. F. McDonagh et al. MOLECULAR CANCER THERAPEUTICS
- Comprehensive molecular portraits of human breast tumours
- (2012) Daniel C. Koboldt et al. NATURE
- p95HER2 and Breast Cancer
- (2011) J. Arribas et al. CANCER RESEARCH
- Zalutumumab in head and neck cancer
- (2011) Ulrike Schick et al. EXPERT OPINION ON BIOLOGICAL THERAPY
- The receptor tyrosine kinase ErbB3 maintains the balance between luminal and basal breast epithelium
- (2011) J. M. Balko et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Transcriptional and posttranslational up-regulation of HER3 (ErbB3) compensates for inhibition of the HER2 tyrosine kinase
- (2011) J. T. Garrett et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- An ErbB3 Antibody, MM-121, Is Active in Cancers with Ligand-Dependent Activation
- (2010) B. Schoeberl et al. CANCER RESEARCH
- Efficacy of Neoadjuvant Cisplatin in Triple-Negative Breast Cancer
- (2010) Daniel P. Silver et al. JOURNAL OF CLINICAL ONCOLOGY
- Randomized Study of Lapatinib Alone or in Combination With Trastuzumab in Women With ErbB2-Positive, Trastuzumab-Refractory Metastatic Breast Cancer
- (2010) Kimberly L. Blackwell et al. JOURNAL OF CLINICAL ONCOLOGY
- Epidermal growth factor receptor as a potential therapeutic target in triple-negative breast cancer
- (2009) B. Corkery et al. ANNALS OF ONCOLOGY
- Current situation of zalutumumab
- (2009) Fernando Rivera et al. EXPERT OPINION ON BIOLOGICAL THERAPY
- Neratinib: an oral, irreversible dual EGFR/HER2 inhibitor for breast and non-small cell lung cancer
- (2009) Prithviraj Bose et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- Internalization and intracellular sorting of the EGF receptor: a model for understanding the mechanisms of receptor trafficking
- (2009) I. H. Madshus et al. JOURNAL OF CELL SCIENCE
- Suppression of breast cancer cell growth by a monoclonal antibody targeting cleavable ErbB4 isoforms
- (2009) M Hollmén et al. ONCOGENE
- The Development of HKI‐272 and Related Compounds for the Treatment of Cancer
- (2008) Allan Wissner et al. ARCHIV DER PHARMAZIE
- A Central Role for HER3 in HER2-Amplified Breast Cancer: Implications for Targeted Therapy
- (2008) S. T. Lee-Hoeflich et al. CANCER RESEARCH
- Lapatinib: A dual inhibitor of human epidermal growth factor receptor tyrosine kinases
- (2008) P MEDINA et al. CLINICAL THERAPEUTICS
- Response to Neoadjuvant Therapy and Long-Term Survival in Patients With Triple-Negative Breast Cancer
- (2008) Cornelia Liedtke et al. JOURNAL OF CLINICAL ONCOLOGY
- Cross-Talk Between the ErbB/HER Family and the Type I Insulin-Like Growth Factor Receptor Signaling Pathway in Breast Cancer
- (2008) Quanri Jin et al. JOURNAL OF MAMMARY GLAND BIOLOGY AND NEOPLASIA
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search